nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—CYP2C19—Cyclosporine—focal segmental glomerulosclerosis	0.219	0.432	CbGbCtD
Sitaxentan—CYP2C9—Cyclosporine—focal segmental glomerulosclerosis	0.182	0.359	CbGbCtD
Sitaxentan—CYP3A4—Cyclosporine—focal segmental glomerulosclerosis	0.106	0.209	CbGbCtD
Sitaxentan—EDNRA—EGFR-dependent Endothelin signaling events—EDN1—focal segmental glomerulosclerosis	0.014	0.0802	CbGpPWpGaD
Sitaxentan—Toxicity to various agents—Cyclosporine—focal segmental glomerulosclerosis	0.0108	0.0339	CcSEcCtD
Sitaxentan—Sensation of foreign body—Cyclosporine—focal segmental glomerulosclerosis	0.00949	0.0298	CcSEcCtD
Sitaxentan—Lymphoma—Cyclosporine—focal segmental glomerulosclerosis	0.00885	0.0278	CcSEcCtD
Sitaxentan—Non-Hodgkin's lymphoma—Cyclosporine—focal segmental glomerulosclerosis	0.00885	0.0278	CcSEcCtD
Sitaxentan—Goitre—Cyclosporine—focal segmental glomerulosclerosis	0.00866	0.0271	CcSEcCtD
Sitaxentan—EDNRB—Prostaglandin Synthesis and Regulation—EDN1—focal segmental glomerulosclerosis	0.00747	0.0428	CbGpPWpGaD
Sitaxentan—Conjunctival hyperaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00703	0.022	CcSEcCtD
Sitaxentan—EDNRB—Endothelin Pathways—EDN1—focal segmental glomerulosclerosis	0.00692	0.0396	CbGpPWpGaD
Sitaxentan—Pancreatitis acute—Cyclosporine—focal segmental glomerulosclerosis	0.0067	0.021	CcSEcCtD
Sitaxentan—EDNRB—Endothelins—TRPC6—focal segmental glomerulosclerosis	0.00637	0.0365	CbGpPWpGaD
Sitaxentan—Night sweats—Cyclosporine—focal segmental glomerulosclerosis	0.00573	0.018	CcSEcCtD
Sitaxentan—EDNRB—Peptide GPCRs—AGTR2—focal segmental glomerulosclerosis	0.00557	0.0319	CbGpPWpGaD
Sitaxentan—Gingival bleeding—Cyclosporine—focal segmental glomerulosclerosis	0.00545	0.0171	CcSEcCtD
Sitaxentan—EDNRA—Prostaglandin Synthesis and Regulation—EDN1—focal segmental glomerulosclerosis	0.00535	0.0306	CbGpPWpGaD
Sitaxentan—EDNRB—Endothelins—GNAQ—focal segmental glomerulosclerosis	0.00532	0.0305	CbGpPWpGaD
Sitaxentan—Polyp—Cyclosporine—focal segmental glomerulosclerosis	0.00508	0.0159	CcSEcCtD
Sitaxentan—EDNRA—Endothelin Pathways—EDN1—focal segmental glomerulosclerosis	0.00495	0.0284	CbGpPWpGaD
Sitaxentan—Psoriasis—Cyclosporine—focal segmental glomerulosclerosis	0.00492	0.0154	CcSEcCtD
Sitaxentan—Cyst—Cyclosporine—focal segmental glomerulosclerosis	0.00463	0.0145	CcSEcCtD
Sitaxentan—Peptic ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.00463	0.0145	CcSEcCtD
Sitaxentan—EDNRA—Endothelins—TRPC6—focal segmental glomerulosclerosis	0.00456	0.0261	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide GPCRs—AGTR1—focal segmental glomerulosclerosis	0.00428	0.0245	CbGpPWpGaD
Sitaxentan—Tongue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00425	0.0133	CcSEcCtD
Sitaxentan—EDNRB—Endothelins—EDN1—focal segmental glomerulosclerosis	0.00413	0.0236	CbGpPWpGaD
Sitaxentan—Herpes zoster—Cyclosporine—focal segmental glomerulosclerosis	0.00411	0.0129	CcSEcCtD
Sitaxentan—Cholestasis—Cyclosporine—focal segmental glomerulosclerosis	0.00407	0.0128	CcSEcCtD
Sitaxentan—Fungal infection—Cyclosporine—focal segmental glomerulosclerosis	0.004	0.0126	CcSEcCtD
Sitaxentan—EDNRA—Peptide GPCRs—AGTR2—focal segmental glomerulosclerosis	0.00398	0.0228	CbGpPWpGaD
Sitaxentan—Skin ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.00397	0.0125	CcSEcCtD
Sitaxentan—Gingivitis—Cyclosporine—focal segmental glomerulosclerosis	0.00394	0.0124	CcSEcCtD
Sitaxentan—Hyperaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00394	0.0124	CcSEcCtD
Sitaxentan—Feeling hot—Cyclosporine—focal segmental glomerulosclerosis	0.00394	0.0124	CcSEcCtD
Sitaxentan—Abscess—Cyclosporine—focal segmental glomerulosclerosis	0.00391	0.0123	CcSEcCtD
Sitaxentan—EDNRA—Endothelins—GNAQ—focal segmental glomerulosclerosis	0.00381	0.0218	CbGpPWpGaD
Sitaxentan—Disturbance in attention—Cyclosporine—focal segmental glomerulosclerosis	0.00357	0.0112	CcSEcCtD
Sitaxentan—Breast pain—Cyclosporine—focal segmental glomerulosclerosis	0.00354	0.0111	CcSEcCtD
Sitaxentan—Amenorrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00352	0.011	CcSEcCtD
Sitaxentan—Musculoskeletal stiffness—Cyclosporine—focal segmental glomerulosclerosis	0.00345	0.0108	CcSEcCtD
Sitaxentan—Viral infection—Cyclosporine—focal segmental glomerulosclerosis	0.00342	0.0107	CcSEcCtD
Sitaxentan—Cellulitis—Cyclosporine—focal segmental glomerulosclerosis	0.0034	0.0107	CcSEcCtD
Sitaxentan—Hyperbilirubinaemia—Cyclosporine—focal segmental glomerulosclerosis	0.0034	0.0107	CcSEcCtD
Sitaxentan—Lacrimation increased—Cyclosporine—focal segmental glomerulosclerosis	0.00336	0.0105	CcSEcCtD
Sitaxentan—Herpes simplex—Cyclosporine—focal segmental glomerulosclerosis	0.00336	0.0105	CcSEcCtD
Sitaxentan—Gout—Cyclosporine—focal segmental glomerulosclerosis	0.00331	0.0104	CcSEcCtD
Sitaxentan—Blood uric acid increased—Cyclosporine—focal segmental glomerulosclerosis	0.00315	0.00987	CcSEcCtD
Sitaxentan—Hiccups—Cyclosporine—focal segmental glomerulosclerosis	0.00309	0.0097	CcSEcCtD
Sitaxentan—EDNRA—Peptide GPCRs—AGTR1—focal segmental glomerulosclerosis	0.00306	0.0175	CbGpPWpGaD
Sitaxentan—Hyperkalaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00304	0.00953	CcSEcCtD
Sitaxentan—Eructation—Cyclosporine—focal segmental glomerulosclerosis	0.00304	0.00953	CcSEcCtD
Sitaxentan—EDNRA—Endothelins—EDN1—focal segmental glomerulosclerosis	0.00295	0.0169	CbGpPWpGaD
Sitaxentan—Candida infection—Cyclosporine—focal segmental glomerulosclerosis	0.00295	0.00926	CcSEcCtD
Sitaxentan—Fluid retention—Cyclosporine—focal segmental glomerulosclerosis	0.00294	0.00921	CcSEcCtD
Sitaxentan—Neoplasm—Cyclosporine—focal segmental glomerulosclerosis	0.0028	0.00877	CcSEcCtD
Sitaxentan—Mental disability—Cyclosporine—focal segmental glomerulosclerosis	0.00268	0.00841	CcSEcCtD
Sitaxentan—EDNRB—G alpha (q) signalling events—TRPC6—focal segmental glomerulosclerosis	0.00267	0.0153	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—AGTR2—focal segmental glomerulosclerosis	0.00262	0.015	CbGpPWpGaD
Sitaxentan—Gastroenteritis—Cyclosporine—focal segmental glomerulosclerosis	0.00253	0.00794	CcSEcCtD
Sitaxentan—Deafness—Cyclosporine—focal segmental glomerulosclerosis	0.00251	0.00787	CcSEcCtD
Sitaxentan—Hepatic failure—Cyclosporine—focal segmental glomerulosclerosis	0.0025	0.00783	CcSEcCtD
Sitaxentan—Increased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00239	0.00749	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—focal segmental glomerulosclerosis	0.00238	0.0137	CbGpPWpGaD
Sitaxentan—Menopausal symptoms—Cyclosporine—focal segmental glomerulosclerosis	0.00238	0.00746	CcSEcCtD
Sitaxentan—Visual disturbance—Cyclosporine—focal segmental glomerulosclerosis	0.00237	0.00743	CcSEcCtD
Sitaxentan—Renal impairment—Cyclosporine—focal segmental glomerulosclerosis	0.00236	0.0074	CcSEcCtD
Sitaxentan—Arthritis—Cyclosporine—focal segmental glomerulosclerosis	0.00231	0.00724	CcSEcCtD
Sitaxentan—Hypoglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.0023	0.00721	CcSEcCtD
Sitaxentan—Cardiac failure—Cyclosporine—focal segmental glomerulosclerosis	0.0023	0.00721	CcSEcCtD
Sitaxentan—Osteoarthritis—Cyclosporine—focal segmental glomerulosclerosis	0.00224	0.00704	CcSEcCtD
Sitaxentan—EDNRB—G alpha (q) signalling events—GNAQ—focal segmental glomerulosclerosis	0.00223	0.0128	CbGpPWpGaD
Sitaxentan—Migraine—Cyclosporine—focal segmental glomerulosclerosis	0.00221	0.00693	CcSEcCtD
Sitaxentan—Blood creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.0021	0.00659	CcSEcCtD
Sitaxentan—Dry skin—Cyclosporine—focal segmental glomerulosclerosis	0.00206	0.00645	CcSEcCtD
Sitaxentan—Abdominal pain upper—Cyclosporine—focal segmental glomerulosclerosis	0.00205	0.00643	CcSEcCtD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—AGTR2—focal segmental glomerulosclerosis	0.00205	0.0117	CbGpPWpGaD
Sitaxentan—EDNRB—G alpha (q) signalling events—AGTR1—focal segmental glomerulosclerosis	0.00204	0.0117	CbGpPWpGaD
Sitaxentan—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00203	0.00636	CcSEcCtD
Sitaxentan—Cramp muscle—Cyclosporine—focal segmental glomerulosclerosis	0.00202	0.00634	CcSEcCtD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—AGTR1—focal segmental glomerulosclerosis	0.00201	0.0115	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—GNAQ—focal segmental glomerulosclerosis	0.00199	0.0114	CbGpPWpGaD
Sitaxentan—Muscular weakness—Cyclosporine—focal segmental glomerulosclerosis	0.00198	0.00621	CcSEcCtD
Sitaxentan—EDNRA—G alpha (q) signalling events—TRPC6—focal segmental glomerulosclerosis	0.00191	0.0109	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—AGTR2—focal segmental glomerulosclerosis	0.00187	0.0107	CbGpPWpGaD
Sitaxentan—Bronchitis—Cyclosporine—focal segmental glomerulosclerosis	0.00187	0.00585	CcSEcCtD
Sitaxentan—Abdominal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00186	0.00583	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—focal segmental glomerulosclerosis	0.00182	0.0104	CbGpPWpGaD
Sitaxentan—Dysuria—Cyclosporine—focal segmental glomerulosclerosis	0.00181	0.00569	CcSEcCtD
Sitaxentan—Pollakiuria—Cyclosporine—focal segmental glomerulosclerosis	0.00179	0.00562	CcSEcCtD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	0.00176	0.0101	CbGpPWpGaD
Sitaxentan—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00176	0.0055	CcSEcCtD
Sitaxentan—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00175	0.00549	CcSEcCtD
Sitaxentan—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.00173	0.00542	CcSEcCtD
Sitaxentan—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.00173	0.00542	CcSEcCtD
Sitaxentan—EDNRB—G alpha (q) signalling events—EDN1—focal segmental glomerulosclerosis	0.00173	0.0099	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—focal segmental glomerulosclerosis	0.00171	0.00977	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—EDN1—focal segmental glomerulosclerosis	0.00171	0.00977	CbGpPWpGaD
Sitaxentan—Acute coronary syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00171	0.00535	CcSEcCtD
Sitaxentan—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.0017	0.00533	CcSEcCtD
Sitaxentan—Myocardial infarction—Cyclosporine—focal segmental glomerulosclerosis	0.0017	0.00532	CcSEcCtD
Sitaxentan—Stomatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00169	0.00529	CcSEcCtD
Sitaxentan—Jaundice—Cyclosporine—focal segmental glomerulosclerosis	0.00169	0.00529	CcSEcCtD
Sitaxentan—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.00168	0.00527	CcSEcCtD
Sitaxentan—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.00165	0.00517	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.00164	0.00513	CcSEcCtD
Sitaxentan—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.00163	0.00512	CcSEcCtD
Sitaxentan—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.00162	0.00509	CcSEcCtD
Sitaxentan—EDNRA—G alpha (q) signalling events—GNAQ—focal segmental glomerulosclerosis	0.0016	0.00913	CbGpPWpGaD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.00158	0.00902	CbGpPWpGaD
Sitaxentan—Haemoglobin—Cyclosporine—focal segmental glomerulosclerosis	0.00156	0.00489	CcSEcCtD
Sitaxentan—Rhinitis—Cyclosporine—focal segmental glomerulosclerosis	0.00156	0.00488	CcSEcCtD
Sitaxentan—Hepatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00155	0.00487	CcSEcCtD
Sitaxentan—Haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.00155	0.00487	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—focal segmental glomerulosclerosis	0.00155	0.00885	CbGpPWpGaD
Sitaxentan—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00153	0.00481	CcSEcCtD
Sitaxentan—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00152	0.00477	CcSEcCtD
Sitaxentan—Visual impairment—Cyclosporine—focal segmental glomerulosclerosis	0.0015	0.00469	CcSEcCtD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—AGTR2—focal segmental glomerulosclerosis	0.00147	0.0084	CbGpPWpGaD
Sitaxentan—EDNRA—G alpha (q) signalling events—AGTR1—focal segmental glomerulosclerosis	0.00146	0.00835	CbGpPWpGaD
Sitaxentan—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.00145	0.00454	CcSEcCtD
Sitaxentan—Flushing—Cyclosporine—focal segmental glomerulosclerosis	0.00144	0.00452	CcSEcCtD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—AGTR1—focal segmental glomerulosclerosis	0.00144	0.00825	CbGpPWpGaD
Sitaxentan—EDNRB—G alpha (q) signalling events—AGT—focal segmental glomerulosclerosis	0.00143	0.00821	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—GNAQ—focal segmental glomerulosclerosis	0.00143	0.00817	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—AGT—focal segmental glomerulosclerosis	0.00142	0.00811	CbGpPWpGaD
Sitaxentan—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00141	0.00442	CcSEcCtD
Sitaxentan—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0014	0.00439	CcSEcCtD
Sitaxentan—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.00137	0.0043	CcSEcCtD
Sitaxentan—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00136	0.00427	CcSEcCtD
Sitaxentan—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.00135	0.00424	CcSEcCtD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.00135	0.00773	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.00134	0.00766	CbGpPWpGaD
Sitaxentan—Tension—Cyclosporine—focal segmental glomerulosclerosis	0.00133	0.00416	CcSEcCtD
Sitaxentan—Nervousness—Cyclosporine—focal segmental glomerulosclerosis	0.00131	0.00412	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—focal segmental glomerulosclerosis	0.0013	0.00747	CbGpPWpGaD
Sitaxentan—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.0013	0.00408	CcSEcCtD
Sitaxentan—CYP2C19—Melatonin metabolism and effects—EDN1—focal segmental glomerulosclerosis	0.0013	0.00742	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—focal segmental glomerulosclerosis	0.00128	0.00735	CbGpPWpGaD
Sitaxentan—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.00127	0.00397	CcSEcCtD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	0.00126	0.00719	CbGpPWpGaD
Sitaxentan—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00125	0.00393	CcSEcCtD
Sitaxentan—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00125	0.00392	CcSEcCtD
Sitaxentan—Agitation—Cyclosporine—focal segmental glomerulosclerosis	0.00124	0.0039	CcSEcCtD
Sitaxentan—EDNRA—G alpha (q) signalling events—EDN1—focal segmental glomerulosclerosis	0.00124	0.00708	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—EDN1—focal segmental glomerulosclerosis	0.00122	0.00699	CbGpPWpGaD
Sitaxentan—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.00122	0.00382	CcSEcCtD
Sitaxentan—Vertigo—Cyclosporine—focal segmental glomerulosclerosis	0.00121	0.00381	CcSEcCtD
Sitaxentan—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.00121	0.00379	CcSEcCtD
Sitaxentan—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.00115	0.00361	CcSEcCtD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.00114	0.00655	CbGpPWpGaD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.00114	0.00358	CcSEcCtD
Sitaxentan—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00114	0.00357	CcSEcCtD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.00113	0.00646	CbGpPWpGaD
Sitaxentan—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.00113	0.00353	CcSEcCtD
Sitaxentan—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.00111	0.00349	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—focal segmental glomerulosclerosis	0.00111	0.00633	CbGpPWpGaD
Sitaxentan—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.0011	0.00346	CcSEcCtD
Sitaxentan—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.0011	0.00344	CcSEcCtD
Sitaxentan—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00108	0.00339	CcSEcCtD
Sitaxentan—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.00108	0.00339	CcSEcCtD
Sitaxentan—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00107	0.00336	CcSEcCtD
Sitaxentan—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.00105	0.0033	CcSEcCtD
Sitaxentan—EDNRB—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.00103	0.00589	CbGpPWpGaD
Sitaxentan—EDNRA—G alpha (q) signalling events—AGT—focal segmental glomerulosclerosis	0.00103	0.00588	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—AGT—focal segmental glomerulosclerosis	0.00101	0.0058	CbGpPWpGaD
Sitaxentan—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.000998	0.00313	CcSEcCtD
Sitaxentan—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.000981	0.00308	CcSEcCtD
Sitaxentan—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.000971	0.00305	CcSEcCtD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.000966	0.00553	CbGpPWpGaD
Sitaxentan—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.000959	0.00301	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.000957	0.00548	CbGpPWpGaD
Sitaxentan—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000952	0.00299	CcSEcCtD
Sitaxentan—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.000951	0.00298	CcSEcCtD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.00095	0.00544	CbGpPWpGaD
Sitaxentan—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.000943	0.00296	CcSEcCtD
Sitaxentan—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.000943	0.00296	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—focal segmental glomerulosclerosis	0.000918	0.00526	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.000909	0.00285	CcSEcCtD
Sitaxentan—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.000876	0.00275	CcSEcCtD
Sitaxentan—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.000872	0.00273	CcSEcCtD
Sitaxentan—EDNRB—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.000872	0.00499	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.000819	0.00469	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.000813	0.00255	CcSEcCtD
Sitaxentan—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.000791	0.00248	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.00076	0.00435	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.000756	0.00433	CbGpPWpGaD
Sitaxentan—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000755	0.00237	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.000736	0.00421	CbGpPWpGaD
Sitaxentan—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.000729	0.00229	CcSEcCtD
Sitaxentan—EDNRB—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.000723	0.00414	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000714	0.00409	CbGpPWpGaD
Sitaxentan—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000701	0.0022	CcSEcCtD
Sitaxentan—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.000696	0.00218	CcSEcCtD
Sitaxentan—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000695	0.00218	CcSEcCtD
Sitaxentan—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.000691	0.00217	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.00069	0.00395	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.000686	0.00393	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.00068	0.00389	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000656	0.00376	CbGpPWpGaD
Sitaxentan—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.000655	0.00205	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.000635	0.00364	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.000624	0.00357	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.000581	0.00333	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.000577	0.0033	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000554	0.00317	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.000544	0.00311	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.000541	0.0031	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.000528	0.00302	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.000518	0.00296	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000511	0.00293	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.000494	0.00283	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.000493	0.00282	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.000491	0.00281	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.00047	0.00269	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.000455	0.0026	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000447	0.00256	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.000416	0.00238	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.000413	0.00236	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.000409	0.00234	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000408	0.00233	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000405	0.00232	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000397	0.00227	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.000378	0.00216	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.000371	0.00213	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.000353	0.00202	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.000341	0.00195	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.00032	0.00183	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000312	0.00178	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.000293	0.00168	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000292	0.00167	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.00029	0.00166	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.000266	0.00152	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	0.000264	0.00151	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—LPL—focal segmental glomerulosclerosis	0.000256	0.00147	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.000244	0.0014	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	0.000243	0.00139	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000223	0.00128	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—AGT—focal segmental glomerulosclerosis	0.000219	0.00126	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—FN1—focal segmental glomerulosclerosis	0.000203	0.00116	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.000191	0.00109	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	0.000189	0.00108	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—LPL—focal segmental glomerulosclerosis	0.000183	0.00105	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	0.000174	0.000995	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.000174	0.000995	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	0.000169	0.000966	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	0.000168	0.00096	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—AGT—focal segmental glomerulosclerosis	0.000157	0.000899	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	0.000153	0.000876	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—FN1—focal segmental glomerulosclerosis	0.000145	0.00083	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	0.000129	0.00074	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	0.000121	0.000691	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	0.000116	0.000666	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	0.000106	0.00061	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	0.000106	0.000607	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	9.95e-05	0.000569	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	9.24e-05	0.000529	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	9.07e-05	0.000519	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—LIPC—focal segmental glomerulosclerosis	8.48e-05	0.000486	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—LIPC—focal segmental glomerulosclerosis	7.74e-05	0.000443	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	7.63e-05	0.000437	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	7.62e-05	0.000436	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CTGF—focal segmental glomerulosclerosis	7.47e-05	0.000428	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	6.96e-05	0.000398	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GNAQ—focal segmental glomerulosclerosis	6.88e-05	0.000394	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CTGF—focal segmental glomerulosclerosis	6.81e-05	0.00039	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GNAQ—focal segmental glomerulosclerosis	6.28e-05	0.000359	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—LPL—focal segmental glomerulosclerosis	5.18e-05	0.000296	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	5.1e-05	0.000292	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—LPL—focal segmental glomerulosclerosis	4.72e-05	0.00027	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	4.49e-05	0.000257	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—AGT—focal segmental glomerulosclerosis	4.43e-05	0.000254	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	4.14e-05	0.000237	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—AGT—focal segmental glomerulosclerosis	4.04e-05	0.000231	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ALB—focal segmental glomerulosclerosis	3.4e-05	0.000195	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	3.11e-05	0.000178	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ALB—focal segmental glomerulosclerosis	3.1e-05	0.000177	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	2.66e-05	0.000153	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	2.04e-05	0.000117	CbGpPWpGaD
